FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Investment analysts at HC Wainwright lifted their FY2025 EPS estimates for Oncolytics Biotech in a research note issued on Monday, November 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.25) per share for the year, up from their previous forecast of ($0.28). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.04) EPS.

ONCY has been the topic of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday. Lake Street Capital began coverage on shares of Oncolytics Biotech in a research report on Wednesday, August 13th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Zacks Research upgraded Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oncolytics Biotech presently has an average rating of “Moderate Buy” and an average target price of $6.25.

Oncolytics Biotech Stock Performance

Oncolytics Biotech stock opened at $1.03 on Wednesday. Oncolytics Biotech has a one year low of $0.33 and a one year high of $1.51. The stock has a fifty day moving average of $1.21 and a 200 day moving average of $0.96. The stock has a market cap of $103.37 million, a PE ratio of -3.81 and a beta of 1.32.

Oncolytics Biotech (NASDAQ:ONCY) last issued its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02.

Institutional Trading of Oncolytics Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of ONCY. Scientech Research LLC bought a new position in Oncolytics Biotech in the 3rd quarter worth $25,000. Seeds Investor LLC lifted its position in shares of Oncolytics Biotech by 17.8% in the second quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock valued at $173,000 after acquiring an additional 33,826 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Oncolytics Biotech in the third quarter valued at about $535,000. 6.82% of the stock is owned by hedge funds and other institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.